The recent first global approval[1]  of ocrelizumab in the US in March 2017 has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs,[2] based on the development milestones tracked in AdisInsight.[3]

In August 2017, ocrelizumab (Ocrevus™), developed by Genentech, was also approved in Canada for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.[4]

“For appropriate patients, Ocrevus will be of great value in reducing the burden of MS”, said Dr. Daniel Selchen, Neurologist and Head of the Division of Neurology at St. Michael’s Hospital in Toronto. “The RRMS Ocrevus clinical trial data show a significant reduction in relapses and disease progression, as well as a good safety profile,” he explained.[4]

For further information related to the first approval of ocrelizumab please visit Drugs[2], or to learn more about the overall development of ocrelizumab across all indications visit AdisInsight.[3]

Image credit:  Ivelin Radkov / Fotolia

Leave a Reply